1163-P: Disparities in Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Utilization in Pediatric Type 2 Diabetes (T2D)
The DOI matches its Crossref record.
Abstract
Introduction and Objective: Disparities in GLP-1 RA use by race/ethnicity and socioeconomic status are documented in adult T2D. To assess if similar disparities occur in pediatric T2D, the association between GLP-1 RA prescriptions and race/ethnicity amongst Medicaid-insured youths with T2D was examined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes
Hundal, J., Ashruf, O. S., Li, H., Basen‐Engquist, K., Kaelber, D. C., & Sukumar, J. S. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00844-6 · Cited by 6
“However, in the general population, signi fi cant socioeconomic disparities have been observed in access to GLP-1RA prescriptions in non-White populations 21 – 23 .”
Metadata
- Authors
- CHU, P. Y., KELLY, A., VAJRAVELU, M. E., HENNESSY, S., & AMARAL, S.
- Affiliations
- Philadelphia, PA, Pittsburgh, PA
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2025-06-20
- Volume
- 74
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- OpenAlex
- W4411291433
- Semantic Scholar
- b4763800c92a93ea63711476482ae616c803dce3
- Cited by
- 1
- References
- 0
- Citations by year
- 2025: 1
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pediatric type 2 diabetes, GLP-1 receptor agonists, racial and ethnic disparities, Latino youth, liraglutide, dulaglutide, exenatide, semaglutide, metformin, insulin, health equity, obesity, socioeconomic status
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 1163-P: Disparities in Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Utilization in Pediatric Type 2 Diabetes (T2D). https://app.cochat.ai/papers/10.2337/db25-1163-p
- The paper
- CHU, P. Y., KELLY, A., VAJRAVELU, M. E., HENNESSY, S., & AMARAL, S. (2025). 1163-P: Disparities in Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Utilization in Pediatric Type 2 Diabetes (T2D). Diabetes. https://doi.org/10.2337/db25-1163-p
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.